# EDGAR Filing Document

**Accession Number:** 0001131343
**File Stem:** 0001437749-26-013732
**Filing Date:** 2026-4
**Character Count:** 88282
**Document Hash:** a46220532739948e5d1761b80731c712
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-26-013732.hdr.sgml**: 20260429

**ACCESSION NUMBER**: 0001437749-26-013732

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 8

**CONFORMED PERIOD OF REPORT**: 20260430

**FILED AS OF DATE**: 20260429

**DATE AS OF CHANGE**: 20260429

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALTERITY THERAPEUTICS LTD
- **CENTRAL INDEX KEY:** 0001131343
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C3
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-49843
- **FILM NUMBER:** 26910655

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** LEVEL 3, 460 BOURKE STREET
- **CITY:** MELBOURNE
- **PROVINCE COUNTRY:** C3
- **BUSINESS PHONE:** 61 3 9349 4906

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** LEVEL 3, 460 BOURKE STREET
- **CITY:** MELBOURNE
- **PROVINCE COUNTRY:** C3

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRANA BIOTECHNOLOGY LTD
- **DATE OF NAME CHANGE:** 20010105

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-163**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of April 2026**

**Alterity Therapeutics Limited**

(Name of Registrant)

**Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia**

(Address of Principal Executive Office)

**Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.**

Form 20-F ☒ Form 40-F ☐

**This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No.** [**<u>333-251073</u>**](http://www.sec.gov/Archives/edgar/data/1131343/000121390020040485/ea130838-s8_alteritytherape.htm)**,** [**<u>333-248980</u>**](http://www.sec.gov/Archives/edgar/data/1131343/000121390020027969/ea127207-s8_alteritytherap.htm) **and** [**<u>333-228671</u>**](http://www.sec.gov/Archives/edgar/data/1131343/000114420418063081/tv508429_s-8.htm)**) and our Registration Statements on Form F-3 (Files No.** [**<u>333-274816</u>**](http://www.sec.gov/Archives/edgar/data/1131343/000101376223000033/ea185947-f3_alteritytherape.htm)**,** [**<u>333-251647</u>**](http://www.sec.gov/Archives/edgar/data/1131343/000121390020044324/ea132148-f3_alteritytherape.htm)**,** [**<u>333-231417</u>**](http://www.sec.gov/Archives/edgar/data/1131343/000114420419025615/tv521271_f3.htm) **and** [**<u>333-250076</u>**](http://www.sec.gov/Archives/edgar/data/1131343/000121390020036934/ea129831-f3_alteritytherap.htm)**)**

------

**ALTERITY THERAPEUTICS LIMITED**

**(a development stage enterprise)**

The following exhibits are submitted:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.1 [Notice of General Meeting/Proxy Form](ex_952819.htm)

------

**<u>SIGNATURE</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| **Alterity Therapeutics Limited** | **Alterity Therapeutics Limited** |
| By: | /s/ Julian Babarczy |
|  | Julian Babarczy |
|  | Chairman |

---

Date: April 29, 2026

## Exhibit 99.1

**Exhibit 99.1**

---

| | |
|:---|:---|
| ![image01.jpg](image01.jpg) | All Registry communications to:<br> Automic<br> Group GPO<br> Box 5193<br> Sydney NSW 2001<br> Telephone (free call within Australia): 1300 288 664<br> ASX Code: ATH |

---

29 April 2026

**Upcoming General Meeting of Shareholders**

Dear Shareholder,

Alterity Therapeutics Limited, ACN 080 699 065 (ASX: ATH or "the **Company**"), advises that a General Meeting will be held online at investor.automic.com.au on Friday, 29 May 2026 at 12pm (AEST) (**Meeting**).

**Notice of Meeting**

The Notice of Meeting and Explanatory Memorandum (**Notice**) for the Meeting is available online and can be viewed and downloaded by shareholders of the Company (**Shareholders**) from the Company's website at <u>www.alteritytherapeutics.com</u> or the Company's ASX market announcements platform at www.asx.com.au (ASX: ATH).

In accordance with sections 110C-110K of the Corporations Act 2001 (Cth) (as inserted by the Treasury Laws Amendment (2021 Measures No.1) Act 2021 (Cth), Shareholders will not be sent a hard copy of the Notice or Proxy Form unless Shareholders have already notified the Company that they wish to receive documents such as the Notice and Proxy Form in hard copy.

**Voting by Proxy** 

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; **Online**<br> scan the QR code below using your smartphone<br> ![image02.jpg](image02.jpg) | Lodge the Proxy Form online at <u>https://singleholding.automic.com.au/login</u> by following the instructions:<br> 1. Login to the Automic website using the holding details as shown on your holding statement.<br> 2. Click on 'Meetings' - 'Vote'.<br>To use the online lodgment facility, Shareholders will need their holder number (Securityholder Reference Number (SRN) or Holder Identification Number (HIN)) as shown at the top of your holding statement. |

---

For further information on the online proxy lodgement process, or if you require a hard copy Proxy Form, please contact the Company's Share Registry, Automic Registry Services (**Automic**), at <u>hello@automicgroup.com.au</u> or via phone on 1300 288 664 (within Australia) or +61 2 9698 5414 (overseas).

**Shareholder queries in relation to the Meeting**

Shareholders can contact the Company Secretary, Abby Macnish Niven, with any questions prior to the meeting via email at <u>cfo@alteritytx.com</u>.

Copies of all Meeting related material including the Notice are available to download from the Company's website and the Company's ASX market announcements platform. In the event it is necessary or appropriate for the Company to make alternative arrangements for the Meeting, information will be provided to Shareholders via the ASX and the Company's website.

The Company **strongly encourages Shareholders to lodge a directed proxy form prior to the Meeting.** Questions should also be submitted in advance of the Meeting as this will provide management with the best opportunity to prepare for the Meeting, for example by preparing answers in advance to Shareholders questions. However, votes and questions may also be submitted during the Meeting. Further details of how to participate in the Meeting are set out in the Online Meeting Guide.

**Authorised for ASX release by the Board of Alterity Therapeutics Limited.**

------

**ALTERITY THERAPEUTICS LIMITED** 

**ACN 080 699 065**

**NOTICE OF GENERAL MEETING**

------

Notice is given that the Meeting will be held at:

**TIME**: 12.00pm (AEST)

**DATE**: Friday 29 May 2026

**PLACE**: online at investor.automic.com.au

***The business of the Meeting affects your shareholding and your vote is important.***

***This Notice should be read in its entirety. If Shareholders are in doubt as to how they should vote, they should seek advice from their professional advisers prior to voting.***

***The Directors have determined pursuant to Regulation 7.11.37 of the Corporations Regulations 2001 (Cth) that the persons eligible to vote at the Meeting are those who are registered Shareholders at 7.00pm (AEST) on Wednesday 27 May 2026.***

------

**BUSINESS OF THE MEETING**

------

**AGENDA**

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.** **RESOLUTION 1** – **ELECTION OF DIRECTOR** – **MR JULIAN BABARCZY** 

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

*"That, for the purpose of clause 6.1 of the Constitution and for all other purposes, Mr Julian Babarczy, a Director who was appointed casually on 21 November 2025, retires, and being eligible, is elected as a Director.*"

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.** **RESOLUTION 2** – **ELECTION OF DIRECTOR** – **MS ANN CUNNINGHAM** 

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

*"That, for the purpose of clause 6.1 of the Constitution and for all other purposes, Ms Ann Cunningham, a Director who was appointed as an additional Director on 17 April 2026, retires, and being eligible, is elected as a Director.*"

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.** **RESOLUTION 3** – **CONSOLIDATION OF CAPITAL** 

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

*"That, pursuant to section 254H of the Corporations Act and for all other purposes, Shareholders approve the consolidation of the issued capital of the Company on the basis that:* 

*(a) every fifty (50) Shares be consolidated into one (1) Share; and*

*(b) every fifty (50) Options be consolidated into one (1) Option,* 

*with fractional entitlements rounded up to the nearest whole Security."*

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.** **RESOLUTION 4** – **APPROVAL TO ISSUE OPTIONS TO DIRECTOR** – **MR JULIAN BABARCZY** 

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

*"That, for the purposes of Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue up to 100,000,000 Options (on a pre-Consolidation basis) to Mr Julian Babarczy (and/or his nominee(s)) on the terms and conditions set out in the Explanatory Statement.*"

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.** **RESOLUTION 5** – **APPROVAL TO ISSUE OPTIONS TO MONTOYA PTY LTD ATF BUTTERCUP TRUST** 

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

*"That, for the purposes of Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue up to 50,000,000 Options (on a pre-Consolidation basis) to Montoya Pty Ltd ATF Buttercup Trust (an entity associated with Director, Mr Lawrence Gozlan) (or its nominee(s) on the terms and conditions set out in the Explanatory Statement.*"

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.** **RESOLUTION 6** – **AMENDMENT TO CONSTITUTION** 

To consider and, if thought fit, to pass the following resolution as a **special resolution**:

*"That, for the purposes of section 136(2) of the Corporations Act and for all other purposes, approval is given for the Company to amend its Constitution to include a new clause 2.9 setting the issue cap for issues of Securities under the Plan to 10% of the issued capital of the Company for the purposes of section 1100V(2) of the Corporations Act.*"

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7.** **RESOLUTION 7** – **APPROVAL TO ISSUE SECURITIES UNDER AN INCENTIVE PLAN** 

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

*"That, for the purposes of Listing Rule 7.2 (Exception 13(b)) and for all other purposes, approval is given for the Company to issue up to a maximum of 1,087,541,633 Securities (on a pre-Consolidation basis) under the Plan, on the terms and conditions set out in the Explanatory Statement.*"

------

**Dated: 29 April 2026**

------

**Voting Prohibition Statements**

------

---

| | |
|:---|:---|
| **Resolution 4** – **Approval to**<br> **issue Options to Director** –<br> **Mr Julian Babarczy** | A person appointed as a proxy must not vote, on the basis of that appointment, on this Resolution if:<br> (a) the proxy is either:<br> (i) a member of the Key Management Personnel; or<br> (ii) a Closely Related Party of such a member; and<br> (b) the appointment does not specify the way the proxy is to vote on this Resolution.<br> However, the above prohibition does not apply if:<br> (a) the proxy is the Chair; and<br> (b) the appointment expressly authorises the Chair to exercise the proxy even though this Resolution is connected directly or indirectly with remuneration of a member of the Key Management Personnel. |
| **Resolution 7** – **Approval to**<br> **issue Securities under an**<br> **incentive plan** | A person appointed as a proxy must not vote, on the basis of that appointment, on this Resolution if:<br> (a) the proxy is either:<br> (i) a member of the Key Management Personnel; or<br> (ii) a Closely Related Party of such a member; and<br> (b) the appointment does not specify the way the proxy is to vote on this Resolution.<br> However, the above prohibition does not apply if:<br> (a) the proxy is the Chair; and<br> (b) the appointment expressly authorises the Chair to exercise the proxy even though this Resolution is connected directly or indirectly with remuneration of a member of the Key Management Personnel. |

---

**Voting Exclusion Statements**

------

In accordance with Listing Rule 14.11, the Company will disregard any votes cast in favour of the Resolution set out below by or on behalf of the following persons:

---

| | |
|:---|:---|
| **Resolution 4** – **Approval to**<br> **issue Options to Director** –<br> **Mr Julian Babarczy**  | Mr Julian Babarczy (and/or his nominee(s)) and any other person who will obtain a material benefit as a result of the issue of the securities (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of that person or those persons. |
| **Resolution 5** – **Approval to**<br> **issue Options to Montoya**<br> **Pty Ltd ATF Buttercup Trust** | Montoya Pty Ltd ATF Buttercup Trust (or its nominee(s)) and any other person who will obtain a material benefit as a result of the issue of the securities (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of that person or those persons. |
| **Resolution 7** – **Approval to**<br> **issue Securities under an**<br> **incentive plan**  | A person who is eligible to participate in the employee incentive scheme or an associate of that person or those persons. |

---

However, this does not apply to a vote cast in favour of the Resolution by:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) a person as a proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with the directions given to the proxy or attorney to vote on the Resolution in that way; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the Chair as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

------

**Voting by proxy**

------

To vote by proxy, please complete and sign the enclosed Proxy Form and return by the time and in accordance with the instructions set out on the Proxy Form.

In accordance with section 249L of the Corporations Act, Shareholders are advised that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● each Shareholder has a right to appoint a proxy;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● the proxy need not be a Shareholder of the Company; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● a Shareholder who is entitled to cast two or more votes may appoint two proxies and may specify the proportion or number of votes each proxy is appointed to exercise. If the Shareholder appoints two proxies and the appointment does not specify the proportion or number of the member's votes, then in accordance with section 249X(3) of the Corporations Act, each proxy may exercise one-half of the votes.

Shareholders and their proxies should be aware that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● if proxy holders vote, they must cast all directed proxies as directed; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● any directed proxies which are not voted will automatically default to the Chair, who must vote the proxies as directed.

**Venue and voting information**

------

Shareholders that have an existing account with Automic will be able to watch, listen and vote online.

Shareholders who do not have an account with Automic are strongly encouraged to register for an account **as soon as possible and well in advance of the Meeting** to avoid any delays on the day of the Meeting.

An account can be created via the following link <u>investor.automic.com.au</u> and then clicking on "**register**" and following the prompts. Shareholders will require their holder number (Securityholder Reference Number (SRN) or Holder Identification Number (HIN)) to create an account with Automic.

To access the virtual meeting on the day:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Open your internet browser and go to <u>investor.automic.com.au</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Login with your username and password or click "**register**" if you haven't already created an account. **Shareholders are encouraged to create an account prior to the start of the meeting to ensure there is no delay in attending the virtual meeting.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. After logging in, a banner will display at the bottom of your screen to indicate that the meeting is open for registration, click on "**Register**" when this appears. Alternatively, click on "**Meetings**" on the left-hand menu bar to join the meeting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. Click on "**Join Meeting**" and follow the prompts on screen to register and vote.

Shareholders will be able to vote (see the "Voting virtually at the Meeting" section of this Notice of Meeting below) and ask questions at the virtual meeting.

Shareholders are also encouraged to submit questions in advance of the Meeting to the Company.

Questions must be submitted in writing to Abby Macnish Niven at cfo@alteritytx.com at least 48 hours before the Meeting.

The Company will also provide Shareholders with the opportunity to ask questions during the Meeting in respect to the formal items of business as well as general questions in respect to the Company and its business.

------

**Voting virtually at the Meeting**

------

Shareholders who wish to vote virtually on the day of the Meeting can do so by logging into the Automic shareholder portal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Open your internet browser and go to <u>investor.automic.com.au</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Login using your username and password. If you do not already have an account, click "**Register**" and follow the prompts. **Shareholders are encouraged to register prior to the commencement of the Meeting to avoid delays in accessing the virtual platform.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. After logging in, a banner will appear at the bottom of your screen when the Meeting is open for registration. Click "**Register** ". Alternatively, select Meetings from the left-hand menu.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. Click on "**Join Meeting**" and follow the prompts.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. When the Chair of the Meeting declares the poll open, select the "**Voting**" dropdown menu on the right-hand side of your screen.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. Select either the "**Full**" or "**Allocate**" option to access your electronic voting card.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*7.* Follow the prompts to record your voting direction for each resolution and click "**Submit votes** ". For allocated votes, the number of votes submitted must not exceed your remaining available units.  ***Important*** *: Votes cannot be amended once submitted.* 

For further information on the live voting process please see the **Registration and Voting Guide** at <u>https://www.automicgroup.com.au/virtual-agms/</u>

It is recommended that Shareholders wishing to attend the Meeting log in from 15 to 30 minutes prior to the scheduled start time.

***Should you wish to discuss the matters in this Notice please do not hesitate to contact the Company Secretary on +61 3 9349 4906.***

------

**EXPLANATORY STATEMENT**

------

This Explanatory Statement has been prepared to provide information which the Directors believe to be material to Shareholders in deciding whether or not to pass the Resolutions.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.** **RESOLUTIONS 1 AND 2** – **ELECTION OF DIRECTORS** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.1** **General** 

The Constitution allows the Directors to appoint at any time a person to be a Director either to fill a casual vacancy or as an addition to the existing Directors, but only where the total number of Directors does not at any time exceed the maximum number specified by the Constitution.

Pursuant to the Constitution and Listing Rule 14.4, a director appointed to fill a casual vacancy or as an addition to the board must not hold office (without re-election) past the next annual general meeting of the entity.

Mr Julian Babarczy and Ms Ann Cunningham, having each been appointed by other Directors on 21 November 2025 and 17 April 2026, respectively, in accordance with the Constitution, will each retire in accordance with the Constitution and being eligible, seek election from Shareholders.

If Mr Babarczy and Ms Cunningham are elected at the Meeting, they will not be required to retire and stand for re-election at the Company's next annual general meeting pursuant to clause 6.1(c) of the Constitution and Listing Rule 14.4 (unless otherwise required to retire by rotation).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.2** **Background - Mr Babarczy** 

Further information in relation to Mr Julian Babarczy is set out below.

---

| | |
|:---|:---|
| **Qualifications,**<br> **experience and**<br> **other material**<br> **directorships** | Mr Babarczy is an experienced investment executive and company director with an over 25-year career in Australia's financial markets. He spent over a decade in senior leadership roles at Regal Partners, contributing to the firm's growth from a boutique fund manager to a multi-billion-dollar investment house, where he led or contributed to a range of investment portfolios spanning a wide range of sectors.<br>Since 2020, Mr Babarczy has focused on board leadership and strategic advisory roles, supporting high-growth companies in technology, financial services, natural resources and other innovation-led industries. He possesses significant capital markets expertise, strong governance capabilities and a hands-on approach to assisting companies to scale both operationally and geographically.<br>Mr Babarczy has successfully completed all three of the CFA Charterholder examinations and holds a Bachelor of Business from Monash University. |
| **Term of office** | Mr Babarczy has served as a Director since 21 November 2025. |
| **Independence** | If re-elected, the Board considers that Mr Babarczy will be an independent Director. |
| **Other material**<br> **information** | The Company conducts appropriate checks on the background and experience of candidates before their appointment to the Board. These include checks as to a person's experience, educational qualifications, character, criminal record and bankruptcy history. The Company undertook such checks prior to the appointment of Mr Babarczy. |
| **Board**<br> **recommendation** | Having received an acknowledgement from Mr Babarczy that they will have sufficient time to fulfil their responsibilities as a Director and having reviewed the performance of Mr Babarczy since their appointment to the Board and the skills, knowledge, experience and capabilities required by the Board, the Directors (other than Mr Babarczy) recommend that Shareholders vote in favour of this Resolution. |

---

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.3** **Background - Ms Cunningham** 

Further information in relation to Ms Cunningham is set out below.

---

| | |
|:---|:---|
| **Qualifications,**<br> **experience and**<br> **other material**<br> **directorships** | Ms Cunningham has more than 25 years of pharma/biotech experience having most recently served as Chief Commercial Officer at Vistagen Therapeutics where she also serves on the Board of Directors. Prior to that, Ms Cunningham served as VP of Neurodegenerative Disease and Psychiatry at Teva after 15 years at Lilly where she led several marketing and sales teams. She holds a B.A. in Psychology from Yale University and an M.B.A. from the University of Michigan. She is the Founder and CEO of i3 Strategy Partners. |
| **Term of office** | Ms Cunningham has served as a Director since 17 April 2026. |
| **Independence** | If re-elected, the Board considers that Ms Cunningham will be an independent Director. |
| **Other material**<br> **information** | The Company conducts appropriate checks on the background and experience of candidates before their appointment to the Board. These include checks as to a person's experience, educational qualifications, character, criminal record and bankruptcy history. The Company undertook such checks prior to the appointment of Ms Cunningham. |
| **Board**<br> **recommendation** | Having received an acknowledgement from Ms Cunningham that they will have sufficient time to fulfil their responsibilities as a Director and having reviewed the performance of Ms Cunningham since their appointment to the Board and the skills, knowledge, experience and capabilities required by the Board, the Directors (other than Ms Cunningham) recommend that Shareholders vote in favour of this Resolution. |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.4** **Technical information required by Listing Rule 14.1A** 

If Resolution 1 is passed, Mr Babarczy will be elected to the Board as an independent Director.

If Resolution 1 is not passed, Mr Babarczy will not continue in his role as an independent Director. The Company may seek nominations or otherwise identify suitably qualified candidates to join the Company. As an additional consequence, this may detract from the Board and Company's ability to execute on its strategic vision.

If Resolution 2 is passed, Ms Cunningham will be elected to the Board as an independent Director.

If Resolution 2 is not passed, Ms Cunningham will not continue in her role as an independent Director. The Company may seek nominations or otherwise identify suitably qualified candidates to join the Company. As an additional consequence, this may detract from the Board and Company's ability to execute on its strategic vision.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.** **RESOLUTION 3** – **CONSOLIDATION OF CAPITAL** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.1** **Background** 

This Resolution seeks Shareholder approval for the purposes of section 254H of the Corporations Act and all other purposes to consolidate the Company's issued capital on a 50:1 basis (**Consolidation**).

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.2** **Legal requirements** 

Section 254H of the Corporations Act provides that a company may, by resolution passed in a general meeting, convert all or any of its shares into a larger or smaller number.

Listing Rule 7.20 provides that if an entity proposes to reorganise its capital, it must tell shareholders of each of the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the effect of the proposal on the number of securities and the amount unpaid (if any) of the securities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the proposed treatment of any fractional entitlements arising from the reorganisation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) the proposed treatment of any convertible securities on issue.

Listing Rule 7.21 provides that an entity which has convertible securities (except options) on issue may only reorganise its capital if, in respect of the convertible securities, the number of securities or the conversion price, or both, is reorganised so that the holder of the convertible securities will not receive a benefit that holders of ordinary securities do not receive.

Listing Rule 7.22 provides that where an entity with options on issue undertakes a consolidation of its issued capital, the number of options must be consolidated in the same ratio as the ordinary capital and the exercise price must be amended in inverse proportion to that ratio.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.3** **American Depositary Receipt (ADR)** 

A proportion of the Shares are held in the form of ADRs. Each ADR currently represents an interest in 600 Shares.

The Company intends to instruct the depositary of its ADRs, HSBC, to adjust the ratio of the Company's ADRs in the same proportion as contemplated by this Resolution 3, such that the number of Shares which each ADR will represent on a post-Consolidation basis will be decreased by a factor of 50 from 600 to 12. As such, the Company does not anticipate the price of the ADRs to change proportionally to the Consolidation ratio.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.4** **Effect on capital structure** 

The effect which the Consolidation will have on the Company's capital structure is set out in the table below.

---

| | | |
|:---|:---|:---|
|  | **SHARES** | **OPTIONS<sup>1</sup>** |
| **Pre-Consolidation**  | **10875416329** | **3176850067** |
| **Post-Consolidation<sup>3,4</sup>** | **217508327** | **63537002** |
| Resolution 4 – Issue of Options to Mr Babarczy<sup>2</sup> | Nil | 2000000 |
| Resolution 5 – Issue of Options to Montoya Pty Ltd ATF Buttercup Trust<sup>2</sup> | Nil | 1000000 |
| **Completion of all Resolutions<sup>3,4</sup>** | **217508327** | **66537002** |

---

**Notes:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The terms of these Options are set out in the table below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Assumes Shareholders approve the issue of Resolutions 4 and 5. These figures are reflected on a post-Consolidation basis.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Assumes no other Shares are issued (including on the exercise or conversion of convertible securities).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. Subject to rounding of fractional entitlements in accordance with Section 2.5 below.

The effect that the Consolidation will have on the terms of the convertible securities that are currently on issue (subject to rounding of fractional entitlements) is set out in the tables below:

------

**Quoted Options**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **CLASS** | **EXPIRY DATE** | **PRE-CONSOLIDATION** | **PRE-CONSOLIDATION** | **POST-CONSOLIDATION** | **POST-CONSOLIDATION** |
| **CLASS** | **EXPIRY DATE** | **NUMBER** | **EXERCISE**<br> **PRICE** | **NUMBER** | **EXERCISE**<br> **PRICE** |
| ASX: ATHO | 31 Aug 2026 | 931232089 | AUD$0.01 | 18624642 | AUD$0.50 |
| ASX: ATHOA | 26 Feb 2027 | 1222300911 | AUD$0.028 | 24446019 | AUD$1.40 |

---

**Unquoted Options**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **CLASS** | **EXPIRY DATE** | **PRE-CONSOLIDATION** | **PRE-CONSOLIDATION** | **POST-CONSOLIDATION** | **POST-CONSOLIDATION** |
| **CLASS** | **EXPIRY DATE** | **NUMBER** | **EXERCISE**<br> **PRICE** | **NUMBER** | **EXERCISE**<br> **PRICE** |
| ASX: ATHAAE | 29 Nov 2026 | 10000000 | AUD$0.0375 | 200000 | AUD$1.875 |
| ASX: ATHAAG | 29 Nov 2026 | 11500000 | AUD$0.0238 | 230000 | AUD$1.19 |
| ASX: ATHAE | 8 Aug 2030 | 11500000 | AUD$0.013 | 230000 | AUD$0.65 |
| ASX: ATHAF | 8 Aug 2030 | 312400200 | USD$0.0086 | 6248004 | USD$0.43 |
| ASX: ATHAD | 1 Jul 2030 | 15000000 | AUD$0.01 | 300000 | AUD$0.50 |
| ASX: ATHAAK | 30 Dec 2027 | 170000000 | AUD$0.01 | 3400000 | AUD$0.50 |
| ASX: ATHAAH | 19 Dec 2026 | 8000000 | AUD$0.0105 | 160000 | AUD$0.525 |
| ASX: ATHAB | 13 Mar 2029 | 62500000 | USD$0.0031 | 1250000 | USD$0.155 |
| ASX: ATHAA | 13 Mar 2029 | 20166667 | AUD$0.004 | 403334 | AUD$0.20 |
| ASX: ATHAC | 21 Mar 2029 | 40000200 | USD$0.003 | 800004 | USD$0.15 |
| ASX: ATHAAL | 9 Jan 2031 | 18000000 | AUD$0.008 | 360000 | AUD$0.40 |
| ASX: ATHAAM | 13 Jan 2031 | 43500000 | USD$0.0057 | 870000 | USD$0.285 |
| ASX: Unlisted options | 26 Mar 2031 | 61500000 | USD$0.0057 | 1230000 | USD$0.285 |
| ASX: Unlisted options | 15 April 2031 | 27000000 | AUD$0.009 | 540000 | AUD$0.45 |
| ASX: Unlisted options | 15 April 2031 | 212250000 | USD$0.006 | 4245000 | USD$0.302 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.5** **Fractional entitlements** 

Not all security holders will hold that number of Securities which can be evenly divided by 50. Fractional entitlements will be rounded up to the nearest whole number.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.6** **Indicative timetable** 

If this Resolution is passed, the Consolidation will take effect in accordance with the following timetable (as set out in Appendix 7A (paragraph 7) of the Listing Rules):

---

| | |
|:---|:---|
| **ACTION** | **DATE** |
| Company announces Consolidation and releases Appendix 3A.3 | Wed 29 April 2026 |
| Company sends out the Notice | Wed 29 April 2026 |
| Shareholders approve the Consolidation | Fri 29 May 2026 |
| Company announces Effective Date of Consolidation | Mon 1 June 2026 |
| Effective Date of Consolidation | Mon 1 June 2026 |
| Last day for pre-Consolidation trading | Tue 2 June 2026 |
| Post-Consolidation trading commences on a deferred settlement basis | Wed 3 June 2026 |

---

------

---

| | |
|:---|:---|
| **ACTION** | **DATE** |
| Record Date | Thurs 4 June 2026 |
| Last day for the Company to register transfers on a pre-Consolidation basis |  |
| First day for the Company to update its register and send holding statements to security holders reflecting the change in the number of Securities they hold | Fri 5 June 2026 |
| Last day for the Company to update its register and to send holding statements to security holders reflecting the change in the number of Securities they hold and to notify ASX that this has occurred | Thur 11 June 2026 |

---

The above timetable is indicative only and the Board reserves the right to vary the timetable subject to compliance with the Listing Rules and all other applicable laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.7** **Holding statements** 

From the date that is two Business Days after the Effective Date (as set out in the timetable in Section 2.6 above), all holding statements for Securities will cease to have any effect, except as evidence of entitlement to a certain number of Securities on a post-Consolidation basis.

After the Consolidation becomes effective, the Company will arrange for new holding statements for Securities to be issued to holders of those Securities.

It is the responsibility of each security holder to check the number of Securities held prior to disposal or exercise (as the case may be).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.8** **Taxation** 

It is not considered that any taxation implications will exist for security holders arising from the Consolidation. However, security holders are advised to seek their own tax advice on the effect of the Consolidation and neither the Company, nor its advisers, accept any responsibility for the individual taxation implications arising from the Consolidation.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.** **RESOLUTION 4** – **APPROVAL TO ISSUE OPTIONS TO DIRECTOR** – **MR JULIAN BABARCZY** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.1** **General** 

The Company has agreed, subject to obtaining Shareholder approval, to issue up to 100,000,000 Options (on a pre-Consolidation basis) to Mr Babarczy (or his nominee(s)) on the terms and conditions set out in Schedule 1.

Resolution 4 seeks Shareholder approval for the purposes of Listing Rule 10.11 for the issue of up to 100,000,000 Options (on a pre-Consolidation basis) to Mr Babarczy (or his nominee(s)).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.2** **Chapter 2E of the Corporations Act** 

Chapter 2E of the Corporations Act requires that for a public company, or an entity that the public company controls, to give a financial benefit to a related party of the public company, the public company or entity must:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) obtain the approval of the public company's members in the manner set out in sections 217 to 227 of the Corporations Act; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) give the benefit within 15 months following such approval,

unless the giving of the financial benefit falls within an exception set out in sections 210 to 216 of the Corporations Act.

The issue constitutes giving a financial benefit and Mr Babarczy is a related party of the Company by virtue of being a Director.

The Directors (other than Mr Babarczy who has a material personal interest in the Resolution) consider that Shareholder approval pursuant to Chapter 2E of the Corporations Act is not required in respect of the issue because the agreement to issue the Options, reached as part of the finalisation of the remuneration package for Mr Babarczy, is considered reasonable remuneration in the circumstances and was negotiated on an arm's length basis.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.3** **Listing Rule 10.11** 

Listing Rule 10.11 provides that unless one of the exceptions in Listing Rule 10.12 applies, a listed company must not issue or agree to issue equity securities to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.11.1 a related party;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.11.2 a person who is, or was at any time in the 6 months before the issue or agreement, a substantial (30%+) holder in the company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.11.3 a person who is, or was at any time in the 6 months before the issue or agreement, a substantial (10%+) holder in the company and who has nominated a director to the board of the company pursuant to a relevant agreement which gives them a right or expectation to do so;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.11.4 an associate of a person referred to in Listing Rules 10.11.1 to 10.11.3; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.11.5 a person whose relationship with the company or a person referred to in Listing Rules 10.11.1 to 10.11.4 is such that, in ASX's opinion, the issue or agreement should be approved by its shareholders,

unless it obtains the approval of its shareholders.

The issue falls within Listing Rule 10.11.1 and does not fall within any of the exceptions in Listing Rule 10.12. It therefore requires the approval of Shareholders under Listing Rule 10.11.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.4** **Technical information required by Listing Rule 14.1A** 

If this Resolution is passed, the Company will be able to proceed with the issue within one month after the date of the Meeting (or such later date as permitted by any ASX waiver or modification of the Listing Rules). As approval pursuant to Listing Rule 7.1 is not required for the issue (because approval is being obtained under Listing Rule 10.11), the issue will not use up any of the Company's 15% annual placement capacity.

If this Resolution is not passed, the Company will not be able to proceed with the issue to Mr Babarczy and the Company may be required to consider alternative means of remunerating Mr Babarczy for his role as a Director (which may include cash bonuses or renegotiating the terms of the Options proposed to be issued to Mr Babarczy).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.5** **Technical Information required by Listing Rule 10.13** 

---

| | |
|:---|:---|
| **REQUIRED INFORMATION** | **DETAILS** |
| **Name of the person to**<br> **whom Securities will be**<br> **issued**  | Mr Babarczy (or his nominee(s)). |
| **Categorisation under**<br> **Listing Rule 10.11** | Mr Babarczy falls within the category set out in Listing Rule 10.11.1 as he is a related party of the Company by virtue of being a Director.<br>Any nominee(s) of Mr Babarczy who receives Options may constitute 'associates' for the purposes of Listing Rule 10.11.4. |
| **Number of Securities and**<br> **class to be issued** | Up to 100,000,000 Options (on a pre-Consolidation basis) on the terms and conditions set out in Schedule 1. |
| **Terms of Securities** | The Options will be issued on the terms and conditions set out in Schedule 1. |
| **Date(s) on or by which**<br> **the Securities will be**<br> **issued** | The Company will not issue any Options later than one month after the date of the Meeting (or such later date to the extent permitted by any ASX waiver or modification of the Listing Rules). |

---

------

---

| | | | |
|:---|:---|:---|:---|
| **REQUIRED INFORMATION** | **DETAILS** | **DETAILS** | **DETAILS** |
| **Price or other**<br> **consideration the**<br> **Company will receive for**<br> **the Securities** | The Options will be issued at a nil issue price.<br>The Company will not receive any other consideration in respect of the issue of the Options (other than in respect of funds received on exercise of the Options). | The Options will be issued at a nil issue price.<br>The Company will not receive any other consideration in respect of the issue of the Options (other than in respect of funds received on exercise of the Options). | The Options will be issued at a nil issue price.<br>The Company will not receive any other consideration in respect of the issue of the Options (other than in respect of funds received on exercise of the Options). |
| **Purpose of the issue,**<br> **including the intended**<br> **use of any funds raised**<br> **by the issue** | The purpose of the issue is to provide an equity-based incentive component in the remuneration package for Mr Babarczy, to align the interests of Mr Babarczy with those of Shareholders and to incentivise Mr Babarczy to act in a manner that seeks to enhance the value of the Company. The Options will only have intrinsic value if the Company's share price exceeds the exercise price, thereby providing an incentive for Mr Babarczy to increase Shareholder value. The issue also provides a cost-effective way for the Company to remunerate Mr Babarczy, which will allow the Company to spend a greater proportion of its cash reserves on its operations than it would if alternative cash forms of remuneration were given to Mr Babarczy. | The purpose of the issue is to provide an equity-based incentive component in the remuneration package for Mr Babarczy, to align the interests of Mr Babarczy with those of Shareholders and to incentivise Mr Babarczy to act in a manner that seeks to enhance the value of the Company. The Options will only have intrinsic value if the Company's share price exceeds the exercise price, thereby providing an incentive for Mr Babarczy to increase Shareholder value. The issue also provides a cost-effective way for the Company to remunerate Mr Babarczy, which will allow the Company to spend a greater proportion of its cash reserves on its operations than it would if alternative cash forms of remuneration were given to Mr Babarczy. | The purpose of the issue is to provide an equity-based incentive component in the remuneration package for Mr Babarczy, to align the interests of Mr Babarczy with those of Shareholders and to incentivise Mr Babarczy to act in a manner that seeks to enhance the value of the Company. The Options will only have intrinsic value if the Company's share price exceeds the exercise price, thereby providing an incentive for Mr Babarczy to increase Shareholder value. The issue also provides a cost-effective way for the Company to remunerate Mr Babarczy, which will allow the Company to spend a greater proportion of its cash reserves on its operations than it would if alternative cash forms of remuneration were given to Mr Babarczy. |
| **Remuneration** | The total remuneration package for Mr Babarczy for the previous financial year and the proposed total remuneration package for the current financial year are set out below (including superannuation): | The total remuneration package for Mr Babarczy for the previous financial year and the proposed total remuneration package for the current financial year are set out below (including superannuation): | The total remuneration package for Mr Babarczy for the previous financial year and the proposed total remuneration package for the current financial year are set out below (including superannuation): |
|  | **RELATED PARTY** | &nbsp;&nbsp;&nbsp; **PREVIOUS FINANCIAL**<br> **YEAR ENDED**<br> **30 JUNE 2025** | &nbsp;&nbsp;&nbsp; **CURRENT FINANCIAL**<br> **YEAR ENDING 30 JUNE**<br> **2026** |
|  | Julian Babarczy | AUD$Nil<sup>1</sup> | AUD$79,333<sup>2</sup> |
|  | **Notes:**<br> 1. Mr Babarczy was appointed as a non-executive Director effective 21 November 2025.<br> 2. Package from 21 November to 31 December 2025 - $100,000 plus superannuation; package from 1 January 2026 onward - $120,000 plus superannuation.<br>If the Options the subject of this Resolution are issued, Mr Babarczy's total remuneration package will increase by AUD$820,000 to AUD$899,333, being the value of the Options (based on the Black Scholes methodology). | **Notes:**<br> 1. Mr Babarczy was appointed as a non-executive Director effective 21 November 2025.<br> 2. Package from 21 November to 31 December 2025 - $100,000 plus superannuation; package from 1 January 2026 onward - $120,000 plus superannuation.<br>If the Options the subject of this Resolution are issued, Mr Babarczy's total remuneration package will increase by AUD$820,000 to AUD$899,333, being the value of the Options (based on the Black Scholes methodology). | **Notes:**<br> 1. Mr Babarczy was appointed as a non-executive Director effective 21 November 2025.<br> 2. Package from 21 November to 31 December 2025 - $100,000 plus superannuation; package from 1 January 2026 onward - $120,000 plus superannuation.<br>If the Options the subject of this Resolution are issued, Mr Babarczy's total remuneration package will increase by AUD$820,000 to AUD$899,333, being the value of the Options (based on the Black Scholes methodology). |
| **Summary of material**<br> **terms of agreement to**<br> **issue** | The Options to be issued to Mr Babarczy (and/or his nominee(s)) are not being issued under a formal agreement. | The Options to be issued to Mr Babarczy (and/or his nominee(s)) are not being issued under a formal agreement. | The Options to be issued to Mr Babarczy (and/or his nominee(s)) are not being issued under a formal agreement. |
| **Voting exclusion**<br> **statement** | A voting exclusion statement applies to this Resolution. | A voting exclusion statement applies to this Resolution. | A voting exclusion statement applies to this Resolution. |
| **Voting prohibition**<br> **statement** | A voting prohibition statement applies to this Resolution. | A voting prohibition statement applies to this Resolution. | A voting prohibition statement applies to this Resolution. |

---

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.** **RESOLUTION 5** – **APPROVAL TO ISSUE OPTIONS TO MONTOYA PTY LTD ATF BUTTERCUP TRUST** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.1** **General** 

The Company has agreed, subject to obtaining Shareholder approval, to issue up to 50,000,000 Options (on a pre-Consolidation basis) to Montoya Pty Ltd ATF Buttercup Trust (ABN 16 212 317 787) (**Montoya**) (an entity associated with Director, Mr Lawrence Gozlan) on the terms and conditions set out in Schedule 1.

Resolution 5 seeks Shareholder approval for the purposes of Listing Rule 10.11 for the issue of up to 50,000,000 Options to Montoya, an entity associated with Director, Mr Lawrence Gozlan.

------

The Options are proposed to be issued pursuant to a consultancy services agreement between the Company, Montoya and Mr Gozlan (as the nominated person) (**Consultancy Agreement**).

Pursuant to the Consultancy Agreement, Montoya will provide advice in relation to corporate and strategic matters, including partnering and equity-related discussions, as well as investor relations and public relations, to the Company until 31 December 2026 (unless validly terminated earlier in accordance with the terms of the Consultancy Agreement).

In consideration for these services, the Consultancy Agreement contemplates that the Company will pay/issue to Montoya:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) AUD$200,000 (exclusive of GST) per annum; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) 50,000,000 Options, exercisable at AUD$0.02 each on or before the date which is five years from the date of issue (on a pre-Consolidation basis), subject to Shareholder approval (being the subject of Resolution 5).

The Consultancy Agreement is otherwise on terms and conditions considered standard for an agreement of its kind.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.2** **Chapter 2E of the Corporations Act** 

A summary of Chapter 2E of the Corporations Act is set out in Section 3.2 above.

The issue constitutes giving a financial benefit and Montoya is a related party of the Company by virtue of being an entity controlled by Director, Mr Gozlan.

The Directors (other than Mr Gozlan who has a material personal interest in the Resolution) consider that Shareholder approval pursuant to Chapter 2E of the Corporations Act is not required in respect of the issue because the Consultancy Agreement whereby the Options were agreed to be issued, was negotiated on an arm's length basis.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.3** **Listing Rule 10.11** 

A summary of Listing Rule 10.11 is set out in Section 3.3 above.

The issue falls within Listing Rule 10.11.4 and does not fall within any of the exceptions in Listing Rule 10.12. The issue therefore requires the approval of Shareholders under Listing Rule 10.11.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.4** **Technical information required by Listing Rule 14.1A** 

If this Resolution is passed, the Company will be able to proceed with the issue within one month after the date of the Meeting (or such later date as permitted by any ASX waiver or modification of the Listing Rules). As approval pursuant to Listing Rule 7.1 is not required for the issue (because approval is being obtained under Listing Rule 10.11), the issue will not use up any of the Company's 15% annual placement capacity.

If this Resolution is not passed, the Company will not be able to proceed with the issue, and the Company may be required to renegotiate the terms of the Consultancy Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.5** **Technical Information required by Listing Rule 10.13** 

---

| | |
|:---|:---|
| **REQUIRED INFORMATION** | **DETAILS** |
| **Name of the person to**<br> **whom Securities will be**<br> **issued**  | Montoya (or its nominee(s)). |
| **Categorisation under**<br> **Listing Rule 10.11** | Montoya falls within the category set out in Listing Rule 10.11.4 by virtue of being an entity associated with Director, Mr Gozlan. |

---

------

---

| | |
|:---|:---|
| **REQUIRED INFORMATION** | **DETAILS** |
| **Number of Securities and**<br> **class to be issued** | Up to 50,000,000 Options (on a pre-Consolidation basis) on the terms and conditions set out in Schedule 1. |
| **Terms of Securities** | The Options will be issued on the terms and conditions set out in Schedule 1. |
| **Date(s) on or by which**<br> **the Securities will be**<br> **issued** | The Company will not issue any Options later than one month after the date of the Meeting (or such later date to the extent permitted by any ASX waiver or modification of the Listing Rules). |
| **Price or other**<br> **consideration the**<br> **Company will receive for**<br> **the Securities** | The Options will be issued at a nil issue price, in consideration for services to be provided to the Company under the Consultancy Agreement.<br>The Company will not receive any other consideration in respect of the issue of the Options (other than in respect of funds received on exercise of the Options). |
| **Purpose of the issue,**<br> **including the intended**<br> **use of any funds raised**<br> **by the issue** | The purpose of the issue is to partially satisfy the fees payable under the Consultancy Agreement. |
| **Summary of material**<br> **terms of agreement to**<br> **issue** | The Options are being issued under the Consultancy Agreement, a summary of the material terms of which is set out in Section 4.1. |
| **Voting exclusion**<br> **statement** | A voting exclusion statement applies to this Resolution. |

---

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.** **RESOLUTION 6** – **AMENDMENT TO CONSTITUTION** 

A company may modify or repeal its constitution or a provision of its constitution by special resolution of Shareholders.

Resolution 6 is a special resolution which will enable the Company to amend its existing Constitution (**Amended Constitution**) for the purposes of section 1100(V)(2) of the Corporations Act to permit the Company to issue Securities under employee incentive schemes (including the Plan) up to a maximum of 10% of the issued capital of the Company.

Under the new Division 1A of Part 7.12 of the Corporations Act, which came into effect on 1 October 2022, offers under an employee incentive plan that do not require a monetary payment (e.g., zero exercise price options or performance rights) can be issued without an issue cap. However, offers requiring a monetary payment (whether upon grant or upon exercise/vesting of the awards and issue of the underlying shares) must be accompanied by an 'ESS offer document' and must comply with an issue cap. The cap is set at 5% under the Corporations Act unless raised by a company's constitution. A company may include a higher issue cap in its constitution to allow for more than 5% of securities to be issued under the Plan.

A copy of the Amended Constitution is available for review by Shareholders at the office of the Company. A copy of the Amended Constitution can also be sent to Shareholders upon request to the Company Secretary. Shareholders are invited to contact the Company if they have any queries or concerns.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.** **RESOLUTION 7** – **APPROVAL TO ISSUE SECURITIES UNDER AN INCENTIVE PLAN** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.1** **General** 

This Resolution seeks Shareholder approval for the purposes of Listing Rule 7.2 (Exception 13(b)) for the issue of a maximum of 1,087,541,633 Securities (on a pre-Consolidation basis) under the employee incentive scheme titled "Employee Incentive Securities Plan" (**Plan**).

------

The objective of the Plan is to attract, motivate and retain key employees, contractors and other persons who provide services to the Company, and the Company considers that the adoption of the Plan and the future issue of Securities under the Plan will provide these parties with the opportunity to participate in the future growth of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.2** **Listing Rule 7.1** 

Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of equity securities that a listed company can issue without the approval of its shareholders over any 12-month period to 15% of the fully paid ordinary shares it had on issue at the start of that period.

Listing Rule 7.2 (Exception 13(b)) provides that Listing Rule 7.1 does not apply to an issue of securities under an employee incentive scheme if, within three years before the date of issue of the securities, the holders of the entity's ordinary securities have approved the issue of equity securities under the scheme as exception to Listing Rule 7.1.

Exception 13(b) is only available if and to the extent that the number of equity securities issued under the scheme does not exceed the maximum number set out in the entity's notice of meeting dispatched to shareholders in respect of the meeting at which shareholder approval was obtained pursuant to Listing Rule 7.2 (Exception 13(b)). Exception 13(b) also ceases to be available if there is a material change to the terms of the scheme from those set out in the notice of meeting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.3** **Technical Information required by Listing Rule 14.1A** 

If this Resolution is passed, the Company will be able to issue Securities under the Plan to eligible participants over a period of three years. The issue of any Securities to eligible participants under the Plan (up to the maximum number of Securities stated in Section 5.4 below) will be excluded from the calculation of the number of equity securities that the Company can issue without Shareholder approval under Listing Rule 7.1.

For the avoidance of doubt, the Company must seek Shareholder approval under Listing Rule 10.14 in respect of any future issues of Securities under the Plan to a related party or a person whose relationship with the Company or the related party is, in ASX's opinion, such that approval should be obtained.

If this Resolution is not passed, the Company will be able to proceed with the issue of Securities under the Plan to eligible participants, but any issues of Securities will reduce, to that extent, the Company's capacity to issue equity securities without Shareholder approval under Listing Rule 7.1 for the 12 month period following the issue of the Securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.4** **Technical information required by Listing Rule 7.2 (Exception 13)** 

---

| | |
|:---|:---|
| **REQUIRED INFORMATION** | **DETAILS** |
| **Terms of the Plan**  | A summary of the material terms and conditions of the Plan is set out in Schedule 2. |
| **Number of Securities**<br> **previously issued under**<br> **the Plan** | The Company has issued 362,250,000 Securities under its previous incentive plans titled "2004 ASX Plan" and "2018 American Depositary Share (**ADS**) Option Plan" (**Previous Plans**) since the Company adopted the Previous Plans.<br>The Previous Plans were last approved by Shareholders on 31 March 2025.<br>The Company has not issued any Securities under the new Plan the subject of this Resolution as this is the first time that Shareholder approval is being sought for the adoption of the Plan. |

---

------

---

| | |
|:---|:---|
| **REQUIRED INFORMATION** | **DETAILS** |
| **Maximum number of**<br> **Securities proposed to**<br> **be issued under the Plan** | The maximum number of Securities proposed to be issued under the Plan in reliance on to Listing Rule 7.2 (Exception 13), following Shareholder approval, is 1,087,541,633 Securities (on a pre-Consolidation basis, 21,750,833 Securities on a post-Consolidation basis). It is not envisaged that the maximum number of Securities for which approval is sought will be issued immediately.<br>The Company may also seek Shareholder approval under Listing Rule 10.14 in respect of any future issues of Securities under the Plan to a related party or a person whose relationship with the Company or the related party is, in ASX's opinion, such that approval should be obtained. |
| **Voting exclusion**<br> **statement** | A voting exclusion statement applies to this Resolution. |
| **Voting prohibition**<br> **statement** | A voting prohibition statement applies to this Resolution. |

---

------

**GLOSSARY**

------

**American Depositary Receipt (ADR)** means a security awarded to Participants who are residents of the United States that represents an ownership interest in the Shares of the Company.

**AEST** means Australian Eastern Standard Time as observed in Melbourne, Victoria.

**ASIC** means the Australian Securities & Investments Commission.

**ASX** means ASX Limited (ACN 008 624 691) or the financial market operated by ASX Limited, as the context requires.

**AUD$** means Australian dollars.

**Board** means the current board of directors of the Company.

**Business Day** means Monday to Friday inclusive, except New Year's Day, Good Friday, Easter Monday, Christmas Day, Boxing Day, and any other day that ASX declares is not a business day.

**Chair** means the chair of the Meeting.

**Closely Related Party** of a member of the Key Management Personnel means:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) a spouse or child of the member;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) a child of the member's spouse;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) a dependent of the member or the member's spouse;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) anyone else who is one of the member's family and may be expected to influence the member, or be influenced by the member, in the member's dealing with the entity;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) a company the member controls; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) a person prescribed by the Corporations Regulations 2001 (Cth) for the purposes of the definition of 'closely related party' in the Corporations Act.

**Company** means Alterity Therapeutics Limited (ACN 080 699 065).

**Consolidation** has the meaning given in Section 2.1.

**Constitution** means the Company's constitution.

**Corporations Act** means the *Corporations Act 2001* (Cth).

**Directors** means the current directors of the Company.

**Explanatory Statement** means the explanatory statement accompanying the Notice.

**Key Management Personnel** has the same meaning as in the accounting standards issued by the Australian Accounting Standards Board and means those persons having authority and responsibility for planning, directing and controlling the activities of the Company, or if the Company is part of a consolidated entity, of the consolidated entity, directly or indirectly, including any director (whether executive or otherwise) of the Company, or if the Company is part of a consolidated entity, of an entity within the consolidated group.

**Listing Rules** means the listing rules, market rules and operating rules of a financial market in respect of which the Company's shares are quoted or are the subject of an application for quotation, including but not limited to, the official listing rules of the ASX. With respect to any ADRs, Listing Rules means the listing rules, market rules and operating rules of the exchange in respect to which the ADRs are quoted or subject to an application for quotation.

**Meeting** means the meeting convened by the Notice.

**Notice** means this notice of meeting including the Explanatory Statement and the Proxy Form.

**Option** means an option to acquire a Share.

**Participant** has the meaning given to it in Schedule 2.

------

**Performance Right** means a right to acquire a Share or ADR subject to satisfaction of performance milestones.

**Plan** has the meaning given in Section 6.1.

**Proxy Form** means the proxy form accompanying the Notice.

**Resolutions** means the resolutions set out in the Notice, or any one of them, as the context requires.

**Section** means a section of the Explanatory Statement.

**Security** means a Share or Option (as applicable).

**Share** means a fully paid ordinary share in the capital of the Company.

**Shareholder** means a registered holder of a Share.

**USD$** means United States dollars.

------

**SCHEDULE 1** – **TERMS AND CONDITIONS OF OPTIONS**

------

**1.** **Entitlement** Each Option entitles the holder to subscribe for one Share upon exercise of the Option.

**2.** **Exercise Price** Subject to paragraph 9, the amount payable upon exercise of each Option will be AUD$0.02 (on a pre-Consolidation basis) (**Exercise Price**).

**3.** **Expiry Date** Each Option will expire at 5:00 pm (AEST) on the date which is five years from the date of issue (**Expiry Date**). An Option not exercised before the Expiry Date will automatically lapse on the Expiry Date

**4.** **Exercise Period** The Options are exercisable at any time on or prior to the Expiry Date (**Exercise Period**).

**5.** **Exercise Notice** The Options may be exercised during the Exercise Period by notice in writing to the Company in the manner specified on the Option certificate (**Exercise Notice**) and payment of the Exercise Price for each Option being exercised in Australian currency by electronic funds transfer or the cashless exercise procedure set out in paragraph 6 or other means of payment acceptable to the Company. An Exercise Notice is only effective on and from the later of the date of receipt of the Exercise Notice and, subject to the holder electing for Cashless Exercise, the date of receipt of the payment of the Exercise Price (for each Option being exercised in cleared funds.)

**6.** **Cashless Exercise** Subject to Board approval, in lieu of paying the aggregate Exercise Price for the number of Options specified in the Exercise Notice, the holder of the Options may elect a cashless exercise (**Cashless Exercise**) whereby the Board will issue to the holder that number of Shares (rounded down to the nearest whole number) calculated in accordance with the following formula: ![ex_952820img001.jpg](ex_952820img001.jpg) Where: S = number of Shares to be issued on the exercise of the Options. O = number of Options being exercised. MVS = market value of Shares, being the volume weighted average price per Share traded on the ASX over the five trading days immediately preceding the date of exercise. EP = Exercise Price of the Options. For the avoidance of doubt, if the sum of the above calculation is zero or negative, then the holder will not be entitled to use Cashless Exercise.

**7.** **Exercise Date** An Exercise Notice is only effective on and from the later of the date of receipt of the Exercise Notice and the date of receipt of the payment of the Exercise Price for each Option being exercised in cleared funds (**Exercise Date**).

------

**8.** **Timing of issue of** **Shares on exercise** Within five Business Days after the Exercise Date, the Company will: (a) issue the number of Shares required under these terms and conditions in respect of the number of Options specified in the Exercise Notice and for which cleared funds have been received by the Company; (b) if required, give ASX a notice that complies with section 708A(5)(e) of the Corporations Act, or, if the Company is unable to issue such a notice, lodge with ASIC a prospectus prepared in accordance with the Corporations Act and do all such things necessary to satisfy section 708A(11) of the Corporations Act to ensure that an offer for sale of the Shares does not require disclosure to investors; and (c) if admitted to the official list of ASX at the time, apply for official quotation on ASX of Shares issued pursuant to the exercise of the Options. If a notice delivered under 7(b) for any reason is not effective to ensure that an offer for sale of the Shares does not require disclosure to investors, the Company must, no later than 20 Business Days after becoming aware of such notice being ineffective, lodge with ASIC a prospectus prepared in accordance with the Corporations Act and do all such things necessary to satisfy section 708A(11) of the Corporations Act to ensure that an offer for sale of the Shares does not require disclosure to investors.

**9.** **Shares issued on** **exercise** Shares issued on exercise of the Options rank equally with the then issued shares of the Company.

**10.** **Reorganisation** If there is a reorganisation of the issued share capital of the Company (including any subdivision, consolidation, reduction, return or cancellation of such issued capital of the Company), the rights of the holder will be changed to the extent necessary to comply with the ASX Listing Rules applicable to a reorganisation of capital at the time of the reorganisation.

**11.** **Participation in** **new issues** There are no participation rights or entitlements inherent in the Options and holders will not be entitled to participate in new issues of capital offered to Shareholders during the currency of the Options without exercising the Options.

**12.** **Change in** **exercise price** An Option does not confer the right to a change in Exercise Price or a change in the number of underlying securities over which the Option can be exercised.

**13.** **Transferability** The Options are transferable subject to any restriction or escrow arrangements imposed by ASX or under applicable Australian securities laws.

------

**SCHEDULE 2** – **TERMS AND CONDITIONS OF THE PLAN** 

------

A summary of the material terms of the Company's Plan is set out below.

For the purposes of this summary, any reference to the term *"exercise"* in relation to Performance Rights shall be read and construed as *"converts"*.

---

| | |
|:---|:---|
| **Eligible Participant** | Eligible Participant means a person that is a 'primary participant' (as that term is defined in Division 1A of Part 7.12 of the Corporations Act) in relation to the Company or an Associated Body Corporate (as defined in the Corporations Act) and has been determined by the Board to be eligible to participate in the Plan from time to time, with the Board retaining discretion to determine, at any time, that the person ceases to be an Eligible Participant, which may impact the treatment of any vested or unvested Plan Securities (defined below) in accordance with the Plan. |
| **Purpose** | The purpose of the Plan is to:<br>(a) assist in the reward, retention and motivation of Eligible Participants;<br>(b) link the reward of Eligible Participants to Shareholder value creation; and<br>(c) align the interests of Eligible Participants with shareholders of the Group (being the Company and each of its Associated Bodies Corporate), by providing an opportunity to Eligible Participants to receive an equity interest in the Company in the form of Shares, Options, Performance Rights or other convertible securities (**Plan Securities**).<br>For a Participant who resides in the United States, the term Plan Security shall include any ADR or convertible security that represents an ADR security in the capital of the Company or any Option, Performance Right or Convertible Security to acquire same. |
| **Maximum number of**<br> **Convertible**<br> **Securities** | The Company will ensure that any invitations under the Plan which are made within Australia and involve monetary consideration comply with the Corporations Act (as modified by any applicable ASIC instruments).<br>The maximum number of equity securities proposed to be issued under the Plan in reliance on Listing Rule 7.2 (Exception 13(b)), following Shareholder approval under Resolution 7, is 1,087,541,633 Securities (on a pre-Consolidation basis, 21,750,833 Securities on a post-Consolidation basis). It is not envisaged that the maximum number of Securities will be issued immediately. |
| **Plan administration** | The Plan will be administered by the Board. The Board may exercise any power or discretion conferred on it by the Plan rules in its sole and absolute discretion (except to the extent that it prevents the Participant relying on the deferred tax concessions under Subdivision 83A-C of the *Income Tax Assessment Act 1997* (Cth)). The Board may delegate its powers and discretion. |
| **Eligibility, invitation**<br> **and application** | The Board may from time to time determine that an Eligible Participant may participate in the Plan and make an invitation to that Eligible Participant to apply for any (or any combination of) the Plan Securities provided under the Plan on such terms and conditions as the Board decides.<br>On receipt of an invitation, an Eligible Participant may apply for the Plan Securities the subject of the invitation by sending a completed application form to the Company. The Board may accept an application from an Eligible Participant in whole or in part.<br>If an Eligible Participant is permitted in the invitation, the Eligible Participant may, by notice in writing to the Board, nominate a party in whose favour the Eligible Participant wishes to renounce the invitation. |

---

------

---

| | |
|:---|:---|
| **Grant of Plan**<br> **Securities** | **Participant** means an Eligible Participant who has been granted any Plan Security under the Plan.<br>The Company will, to the extent that it has accepted a duly completed application, grant the Participant the relevant number and type of Plan Securities, subject to the terms and conditions set out in the invitation, the Plan rules and any ancillary documentation required. |
| **Rights attaching to**<br> **Convertible**<br> **Securities** | A **Convertible Security** represents a right to acquire one or more Plan Shares in accordance with the Plan, including an Option or a Performance Right or, in the case of a Participant who is a resident of the United States, a Security exercisable for an ADR(s) which evidences ownership of Plan Share(s), including any Option or Performance Right..<br>Prior to a Convertible Security being exercised, the holder:<br>(a) does not have any interest (legal, equitable or otherwise) in any Share which may be issued on exercise of the Convertible Security other than as expressly set out in the Plan;<br>(b) is not entitled to receive notice of, vote at or attend a meeting of the shareholders of the Company;<br>(c) is not entitled to receive any dividends declared by the Company; and<br>(d) is not entitled to participate in any new issue of Shares (see Adjustment of Convertible Securities section below). |
| **Restrictions on**<br> **dealing with**<br> **Convertible**<br> **Securities** | Convertible Securities issued under the Plan cannot be sold, assigned, transferred, have a security interest granted over or otherwise dealt with unless in Special Circumstances as defined under the Plan (including in the case of death or total or permanent disability of the holder) with the consent of the Board.<br>A holder must not enter into any arrangement for the purpose of hedging their economic exposure to a Convertible Security that has been granted to them. |
| **Vesting of**<br> **Convertible**<br> **Securities** | Any vesting conditions applicable to the Convertible Securities will be described in the invitation. If all the vesting conditions are satisfied and/or otherwise waived by the Board, a vesting notice will be sent to the Participant by the Company informing them that the relevant Convertible Securities have vested. Unless and until the vesting notice is issued by the Company, the Convertible Securities will not be considered to have vested. For the avoidance of doubt, if the vesting conditions relevant to a Convertible Security are not satisfied and/or otherwise waived by the Board, that security will lapse. |
| **Forfeiture of**<br> **Convertible**<br> **Securities** | Convertible Securities will be forfeited in the following circumstances:<br>(a) in the case of unvested Convertible Securities only, where the holder ceases to be an Eligible Participant (e.g. is no longer employed or their office or engagement is discontinued with the Company and any Associated Bodies Corporate (as defined in the Corporations Act) (the **Group**);<br>(b) in the case of unvested Convertible Securities only, where a Participant acts fraudulently, dishonestly, negligently, in contravention of any Group policy or wilfully breaches their duties to the Group and the Board exercises its discretion to deem some or all of the Convertible Securities held by a Participant to have been forfeited;<br>(c) where there is a failure to satisfy the vesting conditions in accordance with the Plan;<br>(d) on the date the Participant becomes insolvent; or<br>(e) on the expiry date of the Convertible Securities,<br>subject to the discretion of the Board. |

---

------

---

| | |
|:---|:---|
| **Listing of Convertible**<br> **Securities** | Convertible Securities granted under the Plan will not be quoted on the ASX or any other recognised exchange. The Board reserves the right in its absolute discretion to apply for quotation of Convertible Securities granted under the Plan on the ASX or any other recognised exchange. |
| **Exercise of**<br> **Convertible**<br> **Securities and**<br> **cashless exercise** | To exercise a security, the Participant must deliver a signed notice of exercise (**Exercise Notice**) and, subject to a cashless exercise (see next paragraph below), pay the exercise price (if any) to or as directed by the Company, at any time following vesting of the Convertible Securities (if subject to vesting conditions) and prior to the expiry date as set out in the invitation or vesting notice.<br>In the case of Options, subject to the Board's approval, in lieu of paying the aggregate exercise price specified in the Exercise Notice, the Participant may elect a cashless exercise (**Cashless Exercise**) whereby the Board will issue to the Participant that number of Shares (or, if applicable, an ADR granting an ownership interest in Plan Share(s)) (rounded down to the nearest whole number) calculated in accordance with the following formula:<br>![ex_952820img002.jpg](ex_952820img002.jpg)<br>Where:<br>S = number of Shares (or ADRs) to be issued on the exercise of the Options.<br>O = number of Options being exercised.<br>MVS = market value of Shares (or ADRs), being the volume weighted average price per Share traded on the ASX over the five trading days immediately preceding the date of exercise, unless otherwise specified in an invitation or as the rules associated with the trading of an ADR may require.<br>EP = Exercise Price of the Options.<br>For the avoidance of doubt, if the sum of the above calculation is zero or negative, then the holder will not be entitled to use Cashless Exercise.<br>Convertible Securities may not be exercised unless and until that security has vested in accordance with the Plan rules, or such earlier date as set out in the Plan rules. |
| **Timing of issue of**<br> **Shares and**<br> **quotation of Shares**<br> **on exercise** | Within five business days after the issue of a valid notice of exercise by a Participant, the Company will issue or cause to be transferred to that Participant the number of Shares or ADR's to which the Participant is entitled under the Plan rules and issue a substitute certificate for any remaining unexercised Convertible Securities held by that Participant.<br>In the case of a valid exercise of a Convertible Security by a Participant who resides in the United States, the Company will take the proper steps to have an ADR issued by the appropriate financial institution as soon as administratively practicable. |

---

------

---

| | |
|:---|:---|
| **Restriction periods**<br> **and restrictions on**<br> **transfer of Shares on**<br> **exercise** | If the invitation provides that any Shares issued upon the valid exercise of a Convertible Security are subject to any restrictions as to the disposal or other dealing by a Participant for a period, the Board may implement any procedure it deems appropriate to ensure the compliance by the Participant with this restriction.<br>Additionally, Shares issued on exercise of the Convertible Securities are subject to the following restrictions:<br>(a) if the Company is required but is unable to give ASX a notice that complies with section 708A(5)(e) of the Corporations Act, Shares issued on exercise of the Convertible Securities may not be traded until 12 months after their issue unless the Company, at its sole discretion, elects to issue a prospectus pursuant to section 708A(11) of the Corporations Act;<br>(b) all Shares issued on exercise of the Convertible Securities are subject to restrictions imposed by applicable law on dealing in Shares by persons who possess material information likely to affect the value of the Shares and which is not generally available; and<br>(c) all Shares issued on exercise of the Convertible Securities are subject to the terms of the Company's Securities Trading Policy (as set out on the Company's website) |
| **Rights attaching to**<br> **Shares on exercise** | All Shares issued upon exercise of Convertible Securities will rank equally in all respects with the then Shares of the Company.<br>All ADRs issued under this Plan will rank pari passu with all other ADRs issued hereunder and, to the extent possible as determined by the Company, all ADRs will rank pari passu in all respects with the Shares of the class of Shares of the Company that are represented by the ADRs. |
| **Change of control** | Subject at all times to the Listing Rules, if a change of control event occurs (being an event which results in any person (either alone or together with associates) owning more than 50% of the Company's issued capital), or the Board determines that such an event is likely to occur, the Board may in its discretion determine the manner in which any or all of the holder's Convertible Securities will be dealt with, including, without limitation, in a manner that allows the holder to participate in and/or benefit from any transaction arising from or in connection with the change of control event. The Board may specify in the Invitation how the Convertible Securities will be treated on a change of control event occurring, or the Board determining that such event is likely to occur, which may vary depending upon circumstances in which the Participant becomes a leaver and preserve some or all of the Board's discretion under this rule. |
| **Participation in**<br> **entitlements and**<br> **bonus issues** | Subject always to the rights under the following two paragraphs, Participants will not be entitled to participate in new issues of capital offered to holders of Shares such as bonus issues and entitlement issues. |
| **Adjustment for**<br> **bonus issue** | If Shares are issued by the Company by way of bonus issue (other than an issue in lieu of dividends or by way of dividend reinvestment), the Participant is entitled, upon exercise of the Convertible Securities, to receive an issue of as many additional Shares as would have been issued to the holder if the holder held Shares equal in number to the Shares in respect of which the Convertible Securities are exercised.<br>In the case of a Participant who resides in the United States, in the event of an issue of Shares by the Company pro-rata to shareholders by way of a bonus issue, the Company may issue additional ADRs to such Participant that are maintained by such Participant in an allotment of as many additional ADRs as Shares that would have been issued to a shareholder who, on the date for determining entitlements under the bonus issue, held Shares equal in number to the Shares in respect of which the Convertible Securities are exercised. |
| **Reorganisation** | If there is a reorganisation of the issued share capital of the Company (including any subdivision, consolidation, reduction, return or cancellation of such issued capital of the Company), the rights of each Participant holding Convertible Securities will be changed to the extent necessary to comply with the ASX Listing Rules applicable to a reorganisation of capital at the time of the reorganisation. |

---

------

---

| | |
|:---|:---|
| **Buy-Back** | Subject to applicable law, the Company may at any time buy-back Securities in accordance with the terms of the Plan. |
| **Employee Share**<br> **Trust** | The Board may in its sole and absolute discretion use an employee share trust or other mechanism for the purposes of holding Convertible Securities for holders under the Plan and delivering Shares on behalf of holders upon exercise of Convertible Securities. |
| **Amendment of Plan** | Subject to the following paragraph, the Board may at any time amend any provisions of the Plan rules, including (without limitation) the terms and conditions upon which any Plan Securities have been granted under the Plan and determine that any amendments to the Plan rules be given retrospective effect, immediate effect or future effect.<br>No amendment to any provision of the Plan rules may be made if the amendment materially reduces the rights of any Participant as they existed before the date of the amendment, other than an amendment introduced primarily for the purpose of complying with legislation or to correct manifest error or mistake, amongst other things, or is agreed to in writing by all Participants. |
| **Plan duration** | The Plan continues in operation until the Board decides to end it. The Board may from time to time suspend the operation of the Plan for a fixed period or indefinitely and may end any suspension. If the Plan is terminated or suspended for any reason, that termination or suspension must not prejudice the accrued rights of the Participants.<br>If a Participant and the Company (acting by the Board) agree in writing that some or all of the Plan Securities granted to that Participant are to be cancelled on a specified date or on the occurrence of a particular event, then those Plan Securities may be cancelled in the manner agreed between the Company and the Participant. |
| **Income Tax**<br> **Assessment Act** | The Plan is a plan to which Subdivision 83A-C of the *Income Tax Assessment Act 1997* (Cth) applies (subject to the conditions in that Act) except to the extent an invitation provides otherwise. |
| **Withholding** | If required to account for any tax or superannuation amounts for a Participant, a Group member, trustee, or Plan administrator is entitled to withhold or be reimbursed by the Participant for the amount accordingly. |

---

------

![proxy01.jpg](proxy01.jpg)

------

![proxy02.jpg](proxy02.jpg)